Year: 2024

Macerich Announces Pricing of Upsized Public Offering of Common Stock

Written by Customer Service on November 26, 2024. Posted in Public Companies.

SANTA MONICA, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) — The Macerich Company (NYSE: MAC) (the “Company” or “Macerich”) announced today that it has priced an underwritten public offering of 20,000,000 shares of common stock at a price to public of $19.75 per share for expected gross proceeds of approximately $395.0 million. The Company has also granted the underwriters a 30-day option to purchase up to 3,000,000 additional shares of its common stock. This reflects an upsizing of the previously announced offering of 18,000,000 shares of common stock. Subject to customary closing conditions, the offering is expected to close on November 27, 2024. The Company intends to use the net proceeds of this offering, together with cash on hand, including from recent sales under the Company’s “at the market” offering program, to repay the $478.0...

Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies

Written by Customer Service on November 26, 2024. Posted in Public Companies.

Acquisition supports Roche’s Pharma Strategy and allows for a range of potentially first and best-in-class therapies across oncology, immunology, and neurology, uniquely positioning Roche in the new field of donor-derived off-the-shelf cell therapies Roche to acquire Poseida Therapeutics for US $9.00 per share in cash at closing, representing a total equity value of approximately US $1.0 billion Stockholders would also receive a non-tradeable contingent value right (CVR) for up to an aggregate of US $4.00 per share in cash, representing a total deal value of up to approximately US $1.5 billion The transaction is expected to close in the first quarter of 2025Basel, 26 November 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. (“Poseida”,...

PRESS RELEASE: NACON STUDIO GHENT ANNOUNCES HUNTING SIMULATOR 3

Written by Customer Service on November 26, 2024. Posted in Public Companies.

NACON STUDIO GHENT ANNOUNCES HUNTING SIMULATOR 3 Belgian studio Neopica becomes NACON Studio Ghent and reveals its new project Lesquin, 26 November 2024 – NACON and NACON Studio Ghent are pleased to announce Hunting Simulator 3, a new simulation that will delight hunting enthusiasts. Explore the natural landscapes of Colorado and Texas, alone or in a group, and hunt numerous animal species with the help of your faithful hunting dog, when the game launches soon for PlayStation®5, Xbox Series X|S and PC (Steam). Check out the Announcement Trailer: https://youtu.be/kdgO9IDeUxc With almost 10 years’ expertise in hunting games, the studio intends to offer fans of the genre an authentic hunting experience with this third opus. Thanks to feedback from the community, which numbered over 1 million players on the two previous titles, NACON...

Sunward to Finalize Acquisition of New Mexico Based Business from Mountain America Credit Union After Positive Vote

Written by Customer Service on November 26, 2024. Posted in Mergers And Acquisitions.

Acquisition will close in the first quarter of 2025, expanding Sunward’s New Mexico footprint while giving new members access to new services and additional locations.A Media Snippet accompanying this announcement is available by clicking on this link. ALBUQUERQUE, N.M., Nov. 25, 2024 (GLOBE NEWSWIRE) — Sunward, formerly known as Sandia Laboratory Federal Credit Union, and Mountain America Credit Union announced today that after a favorable vote by transitioning Mountain America Credit Union members, the previously announced proposed acquisition is proceeding with a targeted completion in the first quarter of 2025. “We are excited to welcome members and employees from Mountain America Credit Union to Sunward,” said Steph Sherrodd, Sunward President and CEO. “This addition will strengthen our position and ability to deliver on...

PennantPark Investment Corporation Announces Financial Results for the Fourth Quarter and Fiscal Year Ended September 30, 2024 and Upsize of Joint Venture (Amended)

Written by Customer Service on November 26, 2024. Posted in Earnings Releases And Operating Results.

Explanatory Note: PennantPark Investment Corporation (the “Company”) is updating the press release issued by the Company on November 25, 2024 to correct certain information contained therein. The updated release reads: MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) — PennantPark Investment Corporation (NYSE: PNNT) (the “Company”) announced today financial results for the fourth quarter and fiscal year ended September 30, 2024. HIGHLIGHTS Year ended September 30, 2024 ($ in millions, except per share amounts)Assets and Liabilities: Investment portfolio (1) $ 1,328.1 Net assets $ 493.9 Adjusted net asset value per share (2) $ 7.56 Quarterly increase in adjusted net asset value per share (2) 0.5 %GAAP net asset value per share $ 7.56 Quarterly increase in GAAP...

Charlton Aria Acquisition Corporation Announces the Separate Trading of its Class A Ordinary Shares and Rights, Commencing on November 26, 2024

Written by Customer Service on November 26, 2024. Posted in Public Companies.

Wilmington, DE, Nov. 25, 2024 (GLOBE NEWSWIRE) — Charlton Aria Acquisition Corporation (the “Company”) (Nasdaq: CHARU), a blank check company, today announced that, commencing on November 26, 2024, holders of the 8,500,000 units (the “Units”) sold in the Company’s initial public offering (the “Offering”) including Units sold upon a partial exercise of the underwriters’ over-allotment option, may elect to separately trade the Class A ordinary shares and rights included in the Units. Any Units not separated will continue to trade on the NASDAQ Global Market (“NASDAQ”) under the symbol “CHARU.” Any underlying Class A ordinary shares and rights that are separated will trade on the NASDAQ under the symbols “CHAR” and “CHARR,” respectively. Holders of Units will need to have their brokers contact the Company’s transfer agent, Continental...

Urinary Drainage Bags Market to Witness 4.9% CAGR by 2031 | SkyQuest Technology

Written by Customer Service on November 26, 2024. Posted in Mergers And Acquisitions.

Urinary Drainage Bags Market size was valued at USD 2.12 billion in 2023 to USD 3.11 billion by 2031, growing at a CAGR of 4.9% during the forecast period (2024-2031). Westford, USA, Nov. 25, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that Urinary Drainage Bags Market size will attain the value of USD 3.11 Billion by 2031, with a CAGR of 4.9% during the forecast period (2024-2031). The growing older population across the globe, especially in the developed areas, is a main aspect driving the urinary drainage bags industry. As older people are much more likely to be afflicted by urinary incontinence, bladder insufficiency and different chronic situations, the demand for water bottles increases. Furthermore, kidney failure poor performance, prostate problems, and increasing occurrence of different urinary tract infections that frequently...

Healthcare Interoperability Solutions Market to Evolve at a Stellar 12.9% CAGR through 2031 | SkyQuest Technology

Written by Customer Service on November 26, 2024. Posted in Mergers And Acquisitions.

Healthcare Interoperability Solutions Market size was valued at USD 3.84 billion in 2023 to USD 10.13 billion by 2031, growing at a CAGR of 12.9% in the forecast period (2024-2031). Westford, USA, Nov. 25, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the healthcare interoperability solutions market size will attain a value of USD 10.13 billion by 2031, with a CAGR of 12.9% over the forecast period (2024-2031). Rising adoption of electronic health records and high emphasis on improving coordination in healthcare are slated to be factors driving the healthcare interoperability solutions market growth going forward. The development of value-based care models and increasing digitization of the healthcare industry are expected to present new opportunities for healthcare interoperability solutions providers. Browse in-depth TOC on...

ARMLOGI HOLDING CORP. ANNOUNCES UP TO $21 MILLION CONVERTIBLE PROMISSORY NOTES AND $50 MILLION STANDBY EQUITY PURCHASE AGREEMENT

Written by Customer Service on November 26, 2024. Posted in Public Companies.

WALNUT, CA, Nov. 25, 2024 (GLOBE NEWSWIRE) — Armlogi Holding Corp. (“Armlogi” or the “Company”) (Nasdaq: BTOC), a U.S.-based warehousing and logistics service provider that offers a comprehensive package of supply-chain solutions related to warehouse management and order fulfillment, today announced that it has entered into a Standby Equity Purchase Agreement (the “SEPA”), with YA II PN, Ltd. (“YA”), a fund managed by Yorkville Advisors Global, LP. Pursuant to the terms of the SEPA, YA is committed to purchase up to $50 million (the “Commitment Amount”) of the Company’s common stock (the “Common Stock”) at any time during the two-year period following the execution date of the SEPA, by delivering written notice to YA (an “Advance Notice”). Pursuant to the SEPA, YA will advance to the Company, subject to the satisfaction of certain...

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference

Written by Customer Service on November 25, 2024. Posted in Public Companies.

TEL AVIV, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva’s President and CEO, and Eric Hughes, Teva’s Executive Vice President of Global R&D and Chief Medical Officer, will present at the 7th Annual Evercore ISI HealthCONx Conference on Thursday, December 5, 2024. The presentation will begin at 8:20 A.M. Eastern Time. To access a live webcast of the presentation, visit Teva’s Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. An archived version of the webcast will be available within 24 hours after the end of the live discussion. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader, harnessing our generics expertise and stepping up innovation to...

Year: 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals